💰 The agreement could yield Candid up to $925 million in milestones and royalties. Ken Song, CEO of Candid, highlighted its potential for tackling autoimmune diseases.
🌍 This collaboration symbolizes a significant step in innovative cancer treatment developments.
Introduction:
Candid Therapeutics has entered into a strategic partnership with WuXi Biologics, a prominent Contract Development and Manufacturing Organization (CDMO), which grants Candid exclusive global rights to a preclinical trispecific T-cell engager developed from WuXi Biologics’ proprietary platform, WuXiBody™. This collaboration exemplifies a significant advancement in the field of T-cell engagers aimed at enhancing therapeutic options for cancer and autoimmune diseases.
- Candid Therapeutics secures exclusive global rights to a trispecific T-cell engager discovered via WuXi Biologics’ WuXiBody™ platform.
- The agreement allows WuXi Biologics to receive upfront payments and milestone incentives potentially amounting to $925 million, in addition to royalties based on product sales.
- This partnership aims to solidify Candid’s leadership in T-cell engagers targeting specific proteins involved in autoimmune and inflammatory diseases, focusing on BCMA, CD20, and CD19.
- WuXi Biologics highlights its proven capabilities in trispecific and bispecific antibody discoveries, aiming to meet the growing demand for complex therapeutic molecules.
- As part of its expansion strategy, WuXi Biologics aims to enhance the overall efficiency of multispecific antibody development through the innovative features of the WuXiBody™ platform.
Conclusion:
The collaboration between Candid Therapeutics and WuXi Biologics is poised to drive significant advancements in the development of T-cell engagers, potentially expanding treatment avenues for patients with cancer and autoimmune disorders. The financial incentives attached to the partnership, along with WuXi’s innovative platform capabilities, may set new standards in the biopharmaceutical industry, heralding a promising future for multispecific antibody therapies.
